Global Acinetobacter Infections Treatment Market is Segmented By Type (Sulbactam, Carbapenems, Aminoglycosides, Polymyxins, Tetracyclines, Others), By Application (ETX2514, Nacubactam RG6080, Arenicin, VXD-001, Small molecule antibiotic, AR-401 mAB, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global "Acinetobacter Infections Treatment Market" is estimated to reach at a high CAGR during the forecasted period 2024-2031.
Acinetobacter baumannii is a rod-shaped gram-negative coccobacillus bacterium affected by hospital-derived bacterial infection with a weakened immune system. It is often resistant to many commonly prescribed antibiotics.
Market Summary
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Type, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other vital insights. |
| Fastest Growth Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Market Dynamics
Increasing antibiotic combination therapies to treat infections and antibiotic-resistant pathogens is driving the market growth
According to the PLOS Biology Journal, published on September 17, 2020, Antibiotic combination therapies are important for the effective treatment of many types of infections, including those caused by antibiotic-resistant pathogens. Moreover, combination treatment strategies are typically used under the assumption that synergies are maintained over species and strains, even though recent outcomes show that the combined treatment effect is determined by specific drug–strain interactions that can vary extensively and unpredictably, both between and within bacterial species.
The novel CombiANT methodology consists of a 3D-printed agar plate insert that produces defined diffusion landscapes of 3 antibiotics, allowing synergy quantification between all three antibiotic pairs with a single test. In addition, automated image analysis produces fractional inhibitory concentration indices (FICis) with high accuracy and precision. A technical validation with three major pathogens, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, showed the equivalent performance to checkerboard methodology, with the advantage of strongly reduced assay complexity and costs for CombiANT. A synergy screening of 10 antibiotic combinations for 12 E. coli urinary tract infection (UTI) clinical isolates illustrates the need for refined combination treatment strategies. For instance, combinations of trimethoprim (TMP) + nitrofurantoin (NIT) and TMP + mecillinam (MEC) showed synergy, but only for certain individual isolates.
In contrast, MEC + NIT combinations exhibited antagonistic interactions across all tested strains. Therefore data suggest that the CombiANT methodology could allow personalized clinical synergy testing and large-scale screening. Thus, they anticipate that CombiANT will greatly facilitate clinical and basic research of antibiotic synergy, which will drive the market in the forecast period.
High cost of new antibiotic drugs to treat multidrug-resistant bacterial infections is likely to hamper the market growth
According to Springer, published on 13 February 2021, Multidrug-Resistant Gram-negative infections, treatment with old drugs is based on different combinations of colistin, tigecycline, meropenem, and aminoglycosides. Moreover, recent IDSA guidelines recommend as favored treatments for carbapenem-resistant Enterobacterales (CRE) and difficult-to-treat Pseudomonas aeruginosa, mainly new drugs ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol. A treatment plan with any of these would cost double that for the colistin-tigecycline combination and ~ 20 times the cost of colistin monotherapy which is commonly used for Carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Therefore, the annual incremental costs of treating difficult-to-treat Gram-negative bacteria with new drugs ranged from 30 million to over 500 million USD. Thus, from the above factors, the market is expected to get hampered in the forecast period
COVID-19 Impact Analysis
The impact of the COVID-19 pandemic on the spread of antibiotic resistance in health care settings is complicated. In response to a rapid increase in SARS-CoV-2 infections, many health care facilities were chosen mitigation strategies to fight physical space limitations, constrained availability of personnel, shortages in PPE, and a large number of critically ill patients. Recent single-facility reports from the United States and Europe have described the increased acquisition of MDROs among patients hospitalized with COVID-19. For instance, hospital A experienced a large multidrug-resistant CRAB outbreak, primarily involving ICU patients, which extended across multiple units during a surge in COVID-19 cases. Outbreaks of CRAB have been well documented in acute care hospitals, particularly among critically ill patients.
Moreover, the COVID-19 pandemic has required hospitals to take unprecedented measures to maintain continuity of patient care and protect health care personnel from infection. This outbreak highlights that MDROs can spread rapidly in hospitals experiencing surges in COVID-19 cases and cause serious infections in this setting. To reduce the spread of MDROs and the risk of infection for patients, hospitals remained vigilant to prevent and detect clusters of unusual infections and respond when they are detected. Facilities prioritized continuity of core IPC practices to the greatest extent possible during surges in hospitalizations and made every effort to return to normal operating procedures as soon as possible as capacity allows. However, the situation is expected to improve gradually in the forecast period.
Market Segment Analysis
Carbapenems segment is expected to hold the largest market share in this market
The carbapenems segment accounted for the largest market share in 2020, owing to the global increase of carbapenem-resistant A. baumannii which leads to rise in demand for carbapenems as it is an important therapy for serious hospital-acquired infections.
According to the Society for Applied Biology, carbapenems are antimicrobial agents that treat nosocomial infections since they have the most comprehensive spectrum of activity the most prominent potency against Gram-positive and Gram-negative bacteria. Moreover, Acinetobacter species have become a significant cause of acute healthcare-associated diseases and infections. Acinetobacter baumannii is predominantly associated with hospital-acquired infections globally and is an aerobic Gram-negative pathogen that drives infections of the skin, bloodstream, urinary tract and other soft tissues. Carbapenems are safe and effective antibiotics play an important role in medical care, and their development persists as one of the most important advances for healthcare systems. With the start of these agents, the rate of morbidity and mortality associated with the number of life-threatening diseases has significantly reduced, and antibiotics have become the base for therapy related to bacterial infection. Ever since the first β-lactam, penicillin, was introduced to clinical medicine as an option to treat a variety of bacterial infections, β-lactam antibiotics are normally selected as the preferred antimicrobial agents.
Market Geographical Share
North America region holds the largest market share in the global acinetobacter infections treatment market
North America accounted for the largest revenue share in 2020. The growth of this region is due to stringent hospital regulatory policies and increased government support for controlling and preventing antibiotic-resistant infections, which is expected to boost the market in the forecast period. For instance, according to the National Action Plan For Combating Antibiotic-Resistant Bacteria article published in October 2020, the United States government will take the next five years to improve all Americans' health and wellbeing by changing the course of antibiotic resistance.
Moreover, the CARB Task Force employed a One Health approach by engaging U.S. Government agencies that oversee human, animal, and environmental health and promoting collaboration and communication to address antibiotic resistance in every relevant sector and the U.S. government laid out five goals to reduce the incidence and impact of antibiotic-resistant infections including slow the emergence of resistant bacteria and prevent the spread of resistant infections, to strengthen national one Health surveillance efforts to combat resistance, to promote the development and use of rapid and innovative diagnostic tests for identification and characterization of resistant bacteria, stimulate basic and applied research and development for new antibiotics, other therapeutics, and vaccines and to enhance international collaboration and capacities for antibiotic-resistance prevention, surveillance, control and antibiotic research and development. In addition, these goals are pursued by the Federal Departments and Agencies of the CARB Task Force, which is co-chaired by the Secretaries of Health and Human Services, Agriculture, and Defense.
Companies and Competitive Landscape
The acinetobacter infections treatment market is moderately competitive in nature with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Entasis Therapeutics, Atterx Biotherapeutics, Vaxdyn, Roche, LegoChem Biosciences, Adenium Biotech, Aridis Pharmaceuticals, Shionogi and Techulon. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the acinetobacter infections treatment market globally.
Acinetobacter Infections Treatment Market Key Companies to Watch
Roche:
Overview:
Roche is research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics and a frontrunner in diabetes management. Moreover, its personalized healthcare strategy provides medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. The company is the majority shareholder in Chugai Pharmaceutical, Japan.
Product Portfolio:
Roche is focused on medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Moreover, Thirty-two medicines developed by Roche are included in the world health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
